Meiji Yasuda Life Insurance CO Gilead Sciences, Inc. Transaction History

Meiji Yasuda Life Insurance CO

$5.39 Billion
Q3 2024

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$63.15 - $72.88 $2.77 Million - $3.2 Million	-43,909 Reduced 93.27%	3,166 $217,000
Q1 2024 May 15, 2024	SELL	$71.58 - $87.29 $554,172 - $675,799	-7,742 Reduced 14.12%	47,075 $3.45 Million
Q4 2023 Feb 14, 2024	BUY	$73.27 - $83.09 $1.04 Million - $1.18 Million	14,231 Added 35.06%	54,817 $4.44 Million
Q3 2023 Nov 13, 2023	BUY	$73.94 - $80.67 $844,616 - $921,493	11,423 Added 39.17%	40,586 $3.04 Million
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $470,653 - $536,846	6,192 Added 26.96%	29,163 $2.25 Million
Q1 2023 May 10, 2023	BUY	$77.31 - $88.08 $18,554 - $21,139	240 Added 1.06%	22,971 $1.91 Million
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $236,816 - $339,986	3,800 Added 20.07%	22,731 $1.95 Million
Q2 2022 Aug 16, 2022	BUY	$57.72 - $65.01 $219,047 - $246,712	3,795 Added 25.07%	18,931 $1.17 Million
Q1 2022 May 17, 2022	SELL	$57.92 - $72.58 $18,881 - $23,661	-326 Reduced 2.11%	15,136 $900,000
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $63,193 - $71,725	-974 Reduced 5.93%	15,462 $1.12 Million
Q3 2021 Nov 12, 2021	SELL	$67.69 - $73.03 $100,587 - $108,522	-1,486 Reduced 8.29%	16,436 $1.15 Million
Q1 2021 May 14, 2021	SELL	$60.0 - $68.46 $32,460 - $37,036	-541 Reduced 2.93%	17,922 $1.16 Million
Q4 2020 Feb 12, 2021	SELL	$56.65 - $64.55 $331,289 - $377,488	-5,848 Reduced 24.05%	18,463 $1.08 Million
Q3 2020 Nov 12, 2020	SELL	$62.1 - $78.08 $25,709 - $32,325	-414 Reduced 1.67%	24,311 $1.54 Million
Q2 2020 Aug 13, 2020	BUY	$72.34 - $84.0 $318,368 - $369,684	4,401 Added 21.65%	24,725 $1.9 Million
Q1 2020 May 14, 2020	SELL	$62.63 - $80.22 $291,354 - $373,183	-4,652 Reduced 18.63%	20,324 $1.52 Million
Q4 2019 Feb 14, 2020	SELL	$61.62 - $67.78 $164,278 - $180,701	-2,666 Reduced 9.64%	24,976 $1.62 Million
Q3 2019 Nov 13, 2019	BUY	$62.51 - $69.0 $68,135 - $75,210	1,090 Added 4.11%	27,642 $1.75 Million
Q2 2019 Aug 14, 2019	SELL	$61.87 - $69.38 $338,428 - $379,508	-5,470 Reduced 17.08%	26,552 $1.79 Million
Q1 2019 May 14, 2019	SELL	$62.53 - $70.05 $230,172 - $257,854	-3,681 Reduced 10.31%	32,022 $2.08 Million
Q4 2018 Feb 12, 2019	SELL	$60.54 - $79.0 $240,646 - $314,025	-3,975 Reduced 10.02%	35,703 $2.23 Million
Q3 2018 Nov 13, 2018	BUY	$71.28 - $78.92 $659,340 - $730,010	9,250 Added 30.4%	39,678 $3.06 Million
Q2 2018 Aug 13, 2018	BUY	$64.88 - $75.68 $30,493 - $35,569	470 Added 1.57%	30,428 $2.16 Million
Q1 2018 May 14, 2018	SELL	$72.84 - $88.8 $837,660 - $1.02 Million	-11,500 Reduced 27.74%	29,958 $2.26 Million
Q4 2017 Feb 13, 2018	BUY	$71.15 - $83.52 $69,727 - $81,849	980 Added 2.42%	41,458 $2.97 Million
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $2.92 Million - $3.46 Million	40,478	40,478 $3.28 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$11.1 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.7 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$7.07 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.71 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.56 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Meiji Yasuda Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Meiji Yasuda Life Insurance CO with notifications on news.

Account